Oruka Therapeutics CEO sells 25,000 shares

The sales were made under a Rule 10b5-1 plan entered into May 14, 2026, while the reported exercise price was $7.80 per share.

Rhea-AI Filing Summary

Oruka Therapeutics CEO Lawrence Otto Klein exercised warrants for 25,000 common shares on October 1, 2026, at an exercise price of $7.80 per share. On the same date, he sold 25,000 shares in three transactions: 16,246 at a weighted-average price of $83.3979, 8,554 at $84.0256, and 200 at $84.7800. The sales were made under a Rule 10b5-1 trading plan entered into May 14, 2026. His reported position following the warrant transaction was 1,528,513 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 25,000 shares ($1.90M approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Klein Lawrence Otto

Role Chief Executive Officer

Sold 25,000 shs ($2.09M)

Approx. gross sale proceeds $2.09M

Approx. exercise cost $195K

Approx. pre-tax spread $1.90M

Type	Security	Shares	Price	Value
Exercise	Employee Warrant (right to buy) F5	25,000	$0.00	$0.00
Exercise	Common Stock	25,000	$7.80	$195K
Sale	Common Stock F1, F2	16,246	$83.3979	$1.35M
Sale	Common Stock F1, F3	8,554	$84.0256	$719K
Sale	Common Stock F1, F4	200	$84.78	$17K

Holdings After Transaction: Employee Warrant (right to buy) — 1,528,513 contracts (Direct); Common Stock — 923,128 shares (Direct)

Footnotes (5)

1. F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive.
5. F5. The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

Key Figures

Shares acquired through warrant exercise: 25,000 shares Warrant exercise price: $7.80 per share Shares sold at weighted-average price: 16,246 shares at $83.3979 per share +3 more

6 metrics

Shares acquired through warrant exercise 25,000 shares October 1, 2026

Warrant exercise price $7.80 per share October 1, 2026

Shares sold at weighted-average price 16,246 shares at $83.3979 per share October 1, 2026

Shares sold at weighted-average price 8,554 shares at $84.0256 per share October 1, 2026

Shares sold at weighted-average price 200 shares at $84.7800 per share October 1, 2026

Reported shares following warrant transaction 1,528,513 shares Following the October 1, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, weighted average price, Employee Warrant (right to buy)

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Warrant (right to buy) financial

"Employee Warrant (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORKA shares did Lawrence Otto Klein sell, and at what prices?

Lawrence Otto Klein sold 25,000 ORKA shares on October 1, 2026, in three transactions: 16,246 at a weighted-average price of $83.3979, 8,554 at $84.0256, and 200 at $84.7800. The respective transaction price ranges were $82.75 to $83.73, $83.75 to $84.69, and $84.75 to $84.81. The sales were made under a Rule 10b5-1 trading plan entered into May 14, 2026.

What was the ORKA warrant vesting schedule?

The warrant vested as to 1/4 of its underlying shares on April 3, 2025, and as to 1/48 of its underlying shares monthly from April 3, 2025. Klein exercised warrants for 25,000 common shares at $7.80 per share on October 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 07:55 PM Accepted by SEC EDGAR 10/02/2026 - 07:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Lawrence Otto

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2026		M		25,000	A	$7.8	948,128	D
Common Stock	10/01/2026		S(1)		16,246	D	$83.3979(2)	931,882	D
Common Stock	10/01/2026		S(1)		8,554	D	$84.0256(3)	923,328	D
Common Stock	10/01/2026		S(1)		200	D	$84.78(4)	923,128	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Warrant (right to buy)	$7.8	10/01/2026		M			25,000	(5)	07/14/2034	Common Stock	25,000	$0	1,528,513	D

Explanation of Responses:

1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive.

5. The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

	/s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)